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Summary
 
Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that is able to persist for decades
in its host. HCMV has evolved protean countermeasures for anti-HCMV cellular immunity
that facilitate establishment of persistence. Recently it has been shown that HCMV inhibits in-
terferon 
 
g
 
 (IFN-
 
g
 
)–stimulated MHC class II expression, but the mechanism for this effect is
unknown. IFN-
 
g
 
 signal transduction (Jak/Stat pathway) and class II transactivator (CIITA) are
required components for IFN-
 
g
 
–stimulated MHC class II expression. In this study, we demon-
strate that both a clinical isolate and a laboratory strain of HCMV inhibit inducible MHC class
II expression at the cell surface and at RNA level in human endothelial cells and fibroblasts.
Moreover, reverse transcriptase polymerase chain reaction and Northern blot analyses demon-
strate that neither CIITA nor interferon regulatory factor 1 are upregulated in infected cells.
Electrophoretic mobility shift assays reveal a defect in IFN-
 
g
 
 signal transduction, which was
shown by immunoprecipitation to be associated with a striking decrease in Janus kinase 1 (Jak1)
levels. Proteasome inhibitor studies with carboxybenzyl-leucyl-leucyl-leucine vinyl sulfone
suggest an HCMV-associated enhancement of Jak1 protein degradation. This is the first report
of a mechanism for the HCMV-mediated disruption of inducible MHC class II expression and
a direct virus-associated alteration in Janus kinase levels. These findings are yet another example
of the diverse mechanisms by which HCMV avoids immunosurveillance and establishes persis-
tence.
 
H
 
uman cytomegalovirus (HCMV),
 
1
 
 a ubiquitous beta-
herpesvirus, causes extensive morbidity and mortality
in neonatal and immunocompromised patients. In these in-
dividuals, the majority of HCMV-associated disease is the
result of the spread of latent or persistent virus acquired be-
fore immunosuppression (1, 2). Therefore, understanding the
means by which the virus avoids clearance by the immune
system is critical for a complete model of pathogenesis.
The primacy of cell-mediated immunosurveillance in
controlling HCMV infection is established by the promi-
nence of HCMV disease in individuals with impaired cel-
lular immunity (i.e., AIDS patients and transplant recipi-
ents) (1, 2). Although cell-mediated immunity can protect
from disease, it rarely clears the virus from the host. Consis-
tent with this ability to persist, HCMV has evolved multi-
ple mechanisms for escape from cellular immune responses.
HCMV-infected cells are resistant to NK cell lysis through
surface expression of an MHC class I–like molecule (3, 4),
and HCMV escapes CD8
 
1
 
 T lymphocyte immunosurveil-
lance by decreasing MHC class I expression through the
action of three independent HCMV glycoproteins (5–10).
Although NK cells and CD8
 
1
 
 T lymphocytes have been
classically shown to be important in controlling HCMV in-
fection, recent in vivo studies have demonstrated an ex-
panded role for CD4
 
1
 
 T lymphocytes in control of replica-
tion and clearance of the virus (11–13). Moreover, the
profound decrease in CD4
 
1
 
 T lymphocytes in AIDS pa-
tients frequently results in HCMV pneumonia and retinitis
(1, 2). 
CD4
 
1
 
 T lymphocytes recognize antigens presented in
 
1
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g
 
 activation sequence;
HCMV, human cytomegalovirus; IE, immediate-early; IP, immunopre-
cipitation; IRF, IFN regulatory factor; Jak, Janus kinase; L, late; PFA,
phosphonoformic acid; RT, reverse transcribed; Stat, signal transducers
and activators of transcription; Z-L
 
3
 
VS, carboxybenzyl-leucyl-leucyl-leu-
cine vinyl sulfone.
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the context of MHC class II molecules, highly polymor-
phic heterodimers consisting of an 
 
a
 
 and 
 
b
 
 chain. MHC
class II molecules are expressed constitutively on B cells,
monocytes, dendritic cells, and thymic epithelial cells,
whereas IFN-
 
g
 
 is the most potent inducer of MHC class II
expression in many other cell types, including endothelial
cells (ECs) and fibroblasts (14).
MHC class II expression is controlled predominantly at
the level of transcription (14). IFN-
 
g
 
 induces MHC class II
expression by activating the Jak/Stat pathway and upregu-
lating class II transactivator (CIITA). CIITA is believed to
activate transcription by interacting with ubiquitous DNA
binding proteins at MHC class II promoters (14–18). In the
IFN-
 
g
 
 signal transduction (Jak/Stat) pathway, IFN-
 
g
 
 binds
to extracellular heterodimeric receptor subunits IFN-
 
g
 
R1
and IFN-
 
g
 
R2, which are associated intracellularly with the
Janus kinases (Jaks) Jak1 and Jak2, respectively (19, 20).
The binding initiates phosphorylation of tyrosine residues
in Jak1, Jak2, and the cytoplasmic tail of IFN-
 
g
 
R1 (21–24).
Each phosphorylated IFN-
 
g
 
R1 chain becomes a docking
site for a member of the family of signal transducers and ac-
tivators of transcription (Stat), Stat1
 
a
 
 (19, 20). After dock-
ing at the receptor, Stat1
 
a
 
 is phosphorylated by the Jaks
and forms a homodimer known as IFN-
 
g
 
 activation factor
(GAF) (19, 25, 26). GAF migrates to the nucleus where it
binds the IFN-
 
g
 
 activation sequence (GAS) elements
present in the promoters of IFN-
 
g
 
–inducible genes (19).
As with NK cell responses and CD8
 
1
 
 T cell immunosur-
veillance, there is accumulating evidence that HCMV has
evolved a means of escaping CD4
 
1
 
 T cell immunosurveil-
lance as well. HCMV-infected alveolar type II pneu-
mocytes in patients with HCMV pneumonia do not ex-
press MHC class II molecules in vivo (27). In vitro studies
demonstrate that IFN-
 
g
 
 induction of MHC class II expres-
sion is impaired in HCMV-infected ECs and fibroblasts
(28–30). However, the mechanism by which HCMV in-
hibits IFN-
 
g
 
–induced MHC class II expression is un-
known.
In this study, we investigated IFN-
 
g
 
–induced MHC
class II expression in HCMV-infected human ECs and fi-
broblasts. We show that HCMV disrupts IFN-
 
g
 
 induction
of MHC class II expression by inhibiting the Jak/Stat path-
way, a phenomenon associated with decreased Jak1 protein. 
 
Materials and Methods
 
Cells. 
 
Human umbilical vein endothelial cells were isolated
from vessels and propagated as previously described (28). ECs
were infected with HCMV strain VHL/E (31). HCMV-infected
ECs were generated by a dispersion method which yields a cul-
ture of 
 
.
 
95% infected ECs (28). Human embryonic lung fibro-
blasts (MRC-5), passages 22–35, were cultured in Eagle’s mini-
mal essential medium supplemented with 10% fetal bovine serum
(GIBCO BRL, Gaithersburg, MD) at 37
 
8
 
C in a 5% CO
 
2
 
 incuba-
tor. HCMV Towne strain was propagated in MRC-5 at low
multiplicity of infection (MOI) with aliquots frozen at 
 
2
 
80
 
8
 
C
and titer determined as described elsewhere (32). In all experi-
ments, Towne HCMV was incubated (MOI: 3) with fibroblasts
for 2 h at 37
 
8
 
C and free virus was washed off (time 0). To inhibit
HCMV late gene expression, cells were infected with Towne in
the presence of 2 mM phosphonoacetic acid (PFA; Sigma Chem-
ical Co., St. Louis, MO) and 0.6 mM Ganciclovir (GCV; Roche
Labs, Nutley, NJ).
 
Flow Cytometry.
 
Cells were harvested with 0.005% trypsin/0.01%
EDTA, stained with FITC-labeled HLA-DR antibody (Genclone,
Plymouth Meeting, PA) or an isotypic IgG1–FITC conjugate
(Becton Dickinson), and analyzed by flow cytometry on an EPICS
Profile II flow cytometer (Coulter Corp., Hialeah, FL) (27, 28).
 
Northern Blot Analysis.
 
10 
 
m
 
g of total cytoplasmic RNA, iso-
lated by guanidium thiocyanate extraction and cesium chloride
centrifugation, was separated on a 1.4% agarose/0.22 M formal-
dehyde gel and transferred to nylon membranes (Hybond-N;
Amersham Corp., Arlington Heights, IL). For Jak1 detection
only, mRNA from 30 
 
3 
 
10
 
6
 
 fibroblasts was isolated (Invitrogen
Corp., Carlsbad, CA) and fractionated as above. Random prim-
ing (DecaPrime II Kit; Ambion Inc., Austin, TX) of glyceralde-
hyde phosphate dehydrogenase (GAPDH) and HLA-DR
 
a
 
probes was performed (28). PCR labeling was used for interferon
regulatory factor (IRF) 1, glycoprotein (g)B, immediate early 1
(IE1), and Jak1 probes. In brief, 50 ng of full-length human IRF-1,
gB, IE1, or Jak1 was incubated in a 50-
 
m
 
l PCR reaction containing
IRF-1 primers (IRF-1 sense: 5
 
9
 
 CTTCCCTCTTCCACTC-
GGAGTC 3
 
9
 
; IRF-1 antisense: 5
 
9
 
 CTGGTCTTTCACCTC-
CTCGATATCT 3
 
9
 
); gB primers (gB sense: 5
 
9
 
 CACCAAG-
TACCCCTATCGCGT 3
 
9
 
; gB antisense: 5
 
9
 
 TTGTACGAGT-
TGAATTCGCGC 3
 
9
 
); IE1 primers (33); Jak1 primers (Jak1 sense:
5
 
9
 
 GAAACTTTGACAAAACATTACGGTGC 3
 
9
 
; Jak1 antisense:
5
 
9
 
 TCCTTCTTGAGGATCCGATCG 3
 
9
 
); dNTP-dCTP; and 700
nM 
 
a
 
-P32-dCTP (Amersham Corp.). Reaction products were
purified from unincorporated isotope via a Mini Spin G-50 col-
umn (Worthington Biochemical Corp., Freehold, NJ), melted,
hybridized, and detected as previously described (28). After hy-
bridization overnight at 42
 
8
 
C, the final wash was carried out at
56
 
8
 
C with 0.2 
 
3 
 
SSC and 0.1% SDS for 30 min. Autoradiogra-
phy was performed with BioMAX MS film (Eastman Kodak Co.,
Rochester, NY) at 
 
2
 
80
 
8
 
C for 4–8 h.
 
Reverse Transcriptase PCR. 
 
10 
 
m
 
g of cytoplasmic RNA was
treated with 10 U RNase-free DNase (Stratagene Inc., La Jolla,
CA) for 30 min at 37
 
8
 
C followed by phenol/chloroform extrac-
tion and ethanol precipitation at 
 
2
 
80
 
8
 
C. Samples were reverse
transcribed (RT; GIBCO BRL), and one 5-
 
m
 
g aliquot for each
sample served as a no-RT control to control for genomic con-
tamination in subsequent PCR reactions. After heating at 94
 
8
 
C
for 3 min the reaction mixture was cycled 30 times: 1 min at
94
 
8
 
C; 2 min at 60
 
8
 
C; 3 min at 72
 
8
 
C; and a final 10 min elonga-
tion step at 72
 
8
 
C. PCR reactions were performed with 
 
b
 
-actin
(540-bp PCR product), CIITA (680-bp PCR product), and
HLA-DR
 
a
 
 primers (273-bp PCR product) and products were
analyzed on ethidium bromide–stained 2% agarose gels. All PCR
products were cloned into pCRII vector (Invitrogen Corp.) and
sequenced by the dideoxy chain termination method. Primer sets are
as follows: CIITA primers: previously published primers CIITA-2
and CIITA-3 (34); 
 
b
 
-actin sense primer: 5
 
9
 
 GTGGGGCGC-
CCCAGGCACCA 3
 
9
 
; 
 
b
 
-Actin antisense: 5
 
9
 
 CTCCTTAATGT-
CACGCACGATTTC 3
 
9
 
; HLA-DR
 
a
 
 sense: 5
 
9
 
 AAAGCGCTC-
CAACTATACTCCGA 3
 
9
 
; HLA-DR
 
a
 
 antisense: 5
 
9
 
 ACCCT-
GCAGTCGTAAACGTCC 3
 
9
 
.
 
Electrophoretic Mobility Shift Assay. 
 
Nuclear extracts were pre-
pared by a modification of Dignam
 
 
 
et al.
 
 
 
(35). 3 
 
m
 
g of nuclear ex-
tract was combined with 1 
 
m
 
l of 5
 
3
 
 binding buffer, 0.8 
 
m
 
l of poly
(dI-dC), and 1 ml of 32P-labeled IRF-1 GAS element (59 GATC-677 Miller et al.
GATTTCCCCGAAATCATG 39) probe (21). The reaction was
incubated at room temperature for 20 min and resolved on a 6%
nondissociating polyacrylamide gel. For controls, 1 ml (100 ng) of
1003 cold GAS element probe, 1 mg of Stat1a mAb (Santa Cruz
Biotechnology, Santa Cruz, CA), or 1 mg of IgG1 (DAKO
Corp., Carpinteria, CA) was added to the binding reaction before
the addition of radiolabeled probe for competition and supershift
assays, respectively.
Immunoprecipitation and Western Blot Analysis. Immunoprecipi-
tation (IP) was performed as previously described (21, 23). For
Stat1a, 6 3 106 cells per treatment were lysed in IP lysis buffer
consisting of 1% Triton X-100, 0.15 M NaCl, 50 mM Tris (pH
8.0), 50 mM NaF, 5 mM sodium pyrophosphate, 1 mM PMSF, 1
mM orthovanadate, and 5 mg/ml each of pepstatin, leupeptin,
and aprotinin. Stat1a Ab was added to postnuclear lysates and in-
cubated at 48C overnight. For Jak1, Jak2, and IFN-gR1 IP, 12 3
106 cells per treatment were solubilized in IP lysis buffer. For Jak1
and Jak2, 10 mg of rabbit Ig and protein A–Sepharose (Pharmacia
Biotech, Piscataway, NJ) were added to postnuclear lysates and
incubated at 48C overnight. Fresh phosphotyrosine, protease in-
hibitors, and primary antibodies were added to the precleared ly-
sate, followed by another overnight incubation at 48C. Immune
complexes were collected with an excess of protein A–Sepharose
(Jak1, Jak2) or protein G–Sepharose (Stat1a, IFN-gR1) and frac-
tionated under reducing conditions on 7.5% SDS-PAGE (Stat1a,
Jak1, and Jak2) or 12% SDS-PAGE (IFN-gR1). Equal volumes
of lysates from an equal number of cells were resolved by SDS-
PAGE.
For proteasome inhibitor experiments, carboxybenzyl-leucyl-
leucyl-leucine vinyl sulfone (Z-L3VS; gift of Hidde Ploegh, MIT,
Cambridge, MA) was used as previously described (36). Cells at
48 h after infection were incubated with 50 mM Z-L3VS for 12 h
and lysed for IP. Control cells were treated with an equivalent
amount of solvent (DMSO) without Z-L3VS.
Western blot analyses of IP experiments and standard Western
analyses were as follows: Westerns were performed with primary
antibodies (1:1,000) Jak1, Jak2, Stat1a, and IFN-gR1, followed
by 1:3,000 anti–rabbit horseradish peroxidase–conjugated IgG
(Santa Cruz Biotechnology) or horseradish peroxidase–conju-
gated protein (Bio-Rad Laboratories, Hercules, CA), and were
developed using Ultrachemiluminescence (Pierce Chemical Co.,
Rockford, IL). For the standard Western lysates (see Fig. 5 C),
ECs were lysed in 5% SDS, 0.5 M Tris HCl (pH 6.8), 0.5 mM
EDTA, and protease inhibitors. After centrifugation at 15,000
rpm for 15 min, equal volumes of supernatant from an equivalent
number of cells were fractionated by SDS-PAGE and Western
blot analysis was performed as described above.
Results
HCMV Inhibits IFN-g–induced MHC Class II Expres-
sion.  We used human ECs and fibroblasts to investigate
the effect of HCMV on IFN-g–stimulated MHC class II
expression. ECs and fibroblasts are infected by HCMV in
vivo and require IFN-g stimulation to upregulate MHC
class II expression (14, 15, 37, 38). We infected ECs with an
EC-tropic clinical isolate, VHL/E, and fibroblasts were in-
fected with a common laboratory strain of HCMV (Towne).
Our previous studies showed that IFN-g stimulation of
HCMV-infected ECs did not induce MHC class II expres-
sion at the cell surface, in the cytoplasm, or at the RNA
level (28). In this study, our analysis of HCMV-infected fi-
broblasts yielded similar results. Flow cytometry analysis of
HLA-DR surface expression demonstrated that IFN-g
treatment induced MHC class II expression in noninfected
but not in HCMV-infected fibroblasts (Fig. 1 A). UV-
inactivated HCMV did not inhibit MHC class II surface
expression, demonstrating that inhibition of IFN-g–induced
MHC class II expression was dependent upon virus replica-
tion (Fig. 1 A). Northern blot analyses of IFN-g–stimulated
MHC class II RNA expression revealed that noninfected
cells treated with IFN-g accumulated HLA-DRa mRNA,
whereas HCMV-infected cells did not (Fig. 1 B). There-
fore, our findings in fibroblasts paralleled our previous ob-
servations in ECs. That is, HCMV inhibits IFN-g–stimu-
lated MHC class II surface expression and the accumulation
of HLA-DRa RNA.
HCMV Inhibits IFN-g–induced CIITA Expression.  We
hypothesized that one of two known levels of transcrip-
tional control of MHC class II expression, either the Jak/
Stat pathway or CIITA expression, was nonfunctional
given the lack of IFN-g–stimulated MHC class II RNA
upregulation in HCMV-infected cells. CIITA, an IFN-
g–induced transcription factor, is required for activation of
MHC class II promoters and transcription of class II genes
(16). We determined the expression of CIITA in HCMV-
infected ECs and fibroblasts by RT-PCR. Noninfected
cells treated with IFN-g expressed CIITA and HLA-DRa
mRNA, whereas HCMV-infected IFN-g–treated cells did
not (Fig. 2). We next investigated the expression of IRF-1,
an IFN-g–stimulated gene that plays a central role in regu-
lating MHC class I and II expression in vivo, to determine
if HCMV infection globally blocked IFN-g–stimulated
gene expression (39). IRF-1 RNA was upregulated by
IFN-g treatment in noninfected cells but not in HCMV-
infected cells (Fig. 3). These data suggested that there was a
Figure 1. IFN-g–stimulated MHC class II expression is inhibited in
HCMV-infected cells. (A) IFN-g does not induce HLA-DR surface ex-
pression in HCMV-infected fibroblasts. Shown is a bar graph displaying
the mean fluorescent intensity (MFI) of HLA-DR surface expression in
noninfected, sham-infected (inoculated with UV-inactivated HCMV),
and HCMV-infected fibroblasts. Beginning at 12 h after infection, cells
were treated with 200 U/ml IFN-g for 72 h. The mean value of three in-
dependent experiments is displayed with error bars representing the SEM.
(B) IFN-g treatment does not upregulate HLA-DRa RNA in HCMV-
infected cells. IFN-g treatment was identical to that in A. A Northern
analysis is displayed in which IFN-g–stimulated HLA-DRa RNA ex-
pression was compared with glyceraldehyde phosphate dehydrogenase
(GAPDH) expression in fibroblasts.678 Cytomegalovirus Disrupts the Jak/Stat Pathway
general disruption of IFN-g–stimulated gene expression in
HCMV-infected ECs and fibroblasts.
HCMV Inhibits IFN-g–stimulated MHC Class II Expres-
sion by Inhibiting IFN-g Signal Transduction (Jak/Stat Path-
way).  We analyzed IFN-g–stimulated GAF induction to
determine if HCMV disables inducible MHC class II expres-
sion at the level of the Jak/Stat pathway. IFN-g induces
GAF, a homodimer of phosphorylated Stat1a proteins, which
binds GAS elements in the promoters of IFN-g–stimulated
genes and activates transcription (19). IFN-g–stimulated
GAF induction was assayed using electrophoretic mobility
shift assay (EMSA) with the GAS element of the IRF-1
promoter as probe. IFN-g induced GAF in noninfected
cells, but not in HCMV-infected fibroblasts and ECs (Fig.
4). The specificity of our probe was verified by supershift
analysis, in which Stat1a antibody, but not an isotypic
IgG1 control, supershifted the GAF–GAS complex. Fur-
thermore, GAF–GAS complex formation was inhibited by
1003 GAS competitor (Fig. 4).
The formation of GAF is ultimately dependent on the
upstream signaling events of the IFN-g signal transduction
system (Jak/Stat pathway). Stat1a, IFN-gR1, Jak1, and
Jak2 are phosphorylated on tyrosine residues when IFN-g
binds its receptor. We investigated the integrity of this sig-
nal transduction pathway by immunoprecipitation. Nonin-
fected and HCMV-infected fibroblasts were treated with
IFN-g for 30 min and Stat1a, IFN-gR1, Jak2, and Jak1
were immunoprecipitated from whole cell lysates. Each
immunoprecipitate was split in half before Western analyses
of phosphotyrosine (Fig. 5 A) or Stat1a, IFN-gR1, Jak2,
or Jak1 (Fig. 5 B) immunoreactivities. IFN-g stimulated ty-
rosine phosphorylation of Stat1a, IFN-gR1, Jak2, and Jak1
in noninfected cells, but none of these proteins were phos-
phorylated in infected cells (Fig. 5 A). Western analyses of
the immunoprecipitated proteins revealed that Stat1a,
IFN-gR1, and Jak2 were equivalently expressed in nonin-
fected and HCMV-infected cells, whereas there was a dra-
matic decrease of Jak1 protein in infected cells (Fig. 5 B).
These IP experiments in fibroblasts demonstrated a de-
crease of Jak1 protein in HCMV-infected cells. To rule out
the possibility that our antibody was cross-reacting with a
protein immunoprecipitated from HCMV-infected cells,
we analyzed Jak1 expression by standard Western analysis
of whole cell lysates. No Jak1 was detected in infected fi-
broblasts (data not shown). These findings were also ex-
tended to HCMV-infected ECs, which had no detectable
Jak1 protein in contrast to Stat1a (Fig. 5 C).
We performed a Northern blot analysis to determine if
the decrease in Jak1 protein in infected cells correlated with
a change in steady state mRNA. The levels of Jak1 mRNA
were equivalent in noninfected and HCMV-infected fibro-
blasts (Fig. 6), which suggested that JAK-1 was decreased
by a posttranscriptional mechanism.
Recent investigations have demonstrated that the post-
transcriptional decrease in MHC class I heavy chains in in-
fected cells was mediated by the proteasome, a multicata-
lytic proteolytic complex (5, 6, 36). We tested whether
HCMV targeted Jak1 for degradation by a similar mecha-
nism using the proteasome inhibitor Z-L3VS, which co-
valently inhibits the trypsin-like, chymotrypsin-like, and
peptidyl-glutamyl peptidase activities of the proteasome
(36). Noninfected fibroblasts and HCMV-infected fibro-
blasts were treated either with solvent alone (DMSO) or
Z-L3VS for 12 h, and Jak1 was immunoprecipitated. By
Western analysis, Z-L3VS treatment increased the steady
state levels of the Jak1 protein in HCMV-infected fibro-
blasts (Fig. 7). The specificity of this finding was confirmed
by the absence of Jak1 immunoreactivity in the presence of
a blocking peptide. These results suggest that the post-
transcriptional decrease of Jak1 protein in infected cells was
mediated by a degradative process involving the protea-
some.
HCMV Immediate-early or Early Genes Inhibit Inducible
MHC Class II Expression. HCMV has the second largest
genome of the herpesvirus family, encoding .200 proteins
that are expressed in a temporal fashion, e.g., immediate-
early (IE), early (E), and late (L). We examined the role of
late genes in inhibiting IFN-g–stimulated MHC class II ex-
pression using phosphonoformic acid (PFA) and GCV, in-
hibitors of HCMV DNA polymerase. HCMV infection in
the presence of PFA/GCV inhibited the L gene product
gB, without inhibiting IE1 gene expression (Fig. 8 A).
IFN-g–stimulated GAF formation was inhibited in the
presence of these inhibitors (Fig. 8 B). This finding was
consistent with the hypothesis that HCMV IE and/or E
Figure 2. HCMV abrogates IFN-g–stimulated CIITA expression.
IFN-g treatment was as described for Fig. 1 A. RT-PCR analysis of CIITA
expression in noninfected and HCMV-infected fibroblasts (A) and ECs
(B) reveals that IFN-g–stimulated CIITA expression is inhibited in
HCMV-infected cells. 
Figure 3. HCMV inhibits IFN-g–stimulated IRF-1 expression.
Northern analysis of IRF-1 RNA levels shows that IFN-g–stimulated
IRF-1 expression is blocked in infected fibroblasts (A) and ECs (B).679 Miller et al.
genes, but not L genes, inhibit IFN-g–stimulated signal
transduction and MHC class II expression.
Discussion
The studies presented here are the first to reveal a mech-
anism for HCMV inhibition of MHC class II expression.
Specifically, we found that IFN-g–stimulated signal trans-
duction (Jak/Stat pathway) is disabled in infected cells. Jak/
Stat signaling is the most proximal of the levels required for
the induction of MHC class II expression, and its disrup-
tion prevents the upregulation of CIITA and activation of
MHC class II transcription (Fig. 9).
Fibroblasts and ECs are major targets of CMV infection
in vivo (37, 38, 40–42). ECs play a particularly important
role in CMV pathobiology, not only as reservoirs of persis-
tence but as critical components of the dissemination path-
way involving circulating leukocytes (43, 44). However,
ECs also play a vital role in inflammatory responses, and as
such are poised to interact as inducible antigen-presenting
cells with leukocytes. Therefore, it is important for HCMV-
infected ECs to escape cell-mediated immunosurveillance
and persist by inhibiting expression of MHC molecules. It
has been shown that HCMV decreases MHC class I ex-
pression on ECs, for which several mechanisms have been
recently uncovered (5–10). Similarly, we have previously
demonstrated that HCMV inhibits IFN-g–mediated MHC
class II induction on ECs (27–29), and that this inhibition
occurs at the same time after infection as the decrease in
constitutive MHC class I (data not shown). 
Inhibition of IFN-g upregulation of MHC class II ex-
pression has coevolved in divergent viruses including
mouse hepatitis virus, HIV-1, Kirsten murine sarcoma vi-
rus, and measles virus, suggesting that escape from CD41 T
lymphocyte immunosurveillance provides a survival advan-
tage to the pathogen (45, 46). CD41 T cells augment
CD81 T lymphocyte and B lymphocyte responses to viral
infection. There is significant evidence that CD41 T cells
can control CMV infection independent of the CD81 T
cell subset: mice depleted of CD81 T cells halt CMV dis-
semination with similar kinetics to immunocompetent
mice (13), and clearance of CMV from select organs is
Figure 4. IFN-g–stimulated GAF
formation is inhibited in HCMV-
infected cells. At 72 h after infection,
noninfected and HCMV-infected (A)
fibroblasts and (B) ECs were treated
with 200 U/ml IFN-g for 30 min and
then nuclear extracts were recovered.
EMSA binding reactions were per-
formed as described in Materials and
Methods. For controls, 1003 GAS el-
ement competitor, Stat1a Ab, or IgG1
was added to the binding reaction be-
fore the addition of radiolabeled probe.
The supershifted GAF–GAS band is
denoted by *. IFN-g–stimulated GAF
formation is inhibited in infected fi-
broblasts (A, lane 4) and ECs (B, lane 4).
Figure 5. IFN-g–stimulated Jak/Stat signal transduction is inhibited by HCMV. Fibroblasts at 72 h after infection were treated with IFN-g, solubi-
lized in a 1% Triton X-100 lysis buffer, and IPs were performed. Immunoprecipitates were divided in half for Western blot analysis of phosphotyrosine
immunoreactivity (A) or Western blot detection of the immunoprecipitated protein (B). (A) IFN-g stimulates phosphorylation of Stat1a, IFN-gR1,
Jak2, and Jak1 in noninfected cells (lane 2), but none of these proteins are phosphorylated in HCMV-infected cells (lane 4). (B) There is an equivalent
amount of Stat1a, IFN-gR1, and Jak2 protein in noninfected and HCMV-infected cells, but Jak1 protein is decreased in HCMV-infected cells. (C)
Standard SDS lysates from ECs were fractionated by SDS-PAGE and analyzed by Western blot analysis. Jak1 protein is decreased in HCMV-infected cells
in contrast to Stat1a. 680 Cytomegalovirus Disrupts the Jak/Stat Pathway
completely dependent upon the CD41 T cell subset (12,
47). A direct role for CD41 T cells in anti-CMV activity is
supported by the findings of CMV-specific class II–restricted
cytolysis and direct antiviral effects of the CD41 T lym-
phocyte cytokine mileu, specifically IFN-g (11, 12, 48–
50). The release of cytokines from CMV-specific CD41 T
cells has significant direct and immunoregulatory anti-
CMV effects in vivo and in vitro (11–13, 51, 52). Our results
suggest that HCMV may inhibit these direct and indirect
IFN-g antiviral effects by knocking out IFN-g responses at
their most proximal point, the level of IFN-g signal trans-
duction. 
IFN-g signal transduction is dependent upon the func-
tion of Jak1 (53). In mutant cell lines lacking this protein,
IFN-g–stimulated tyrosine phosphorylation of IFN-gR1,
Jak1, Jak2, and Stat1a is inhibited (53). This pattern of
phosphorylation is analogous to what we found in HCMV-
infected cells (Fig. 5), suggesting that the HCMV-associ-
ated posttranscriptional decrease in Jak1 protein results in
inhibition of IFN-g–stimulated MHC class II expression.
Northern analysis of Jak1 mRNA in infected cells revealed
steady state levels equivalent to those in noninfected cells.
This data, in conjunction with experiments with the pro-
teasome inhibitor Z-L3VS, suggest that increased degrada-
tion by the proteasome complex is at least partly responsi-
ble for the decrease in Jak1 protein.
Lastly, we found that CMV IE and/or E genes inhibit
IFN-g–stimulated MHC class II expression by disrupting
IFN-g–mediated Jak/Stat signal transduction. CMV IE and
E genes mediate the majority of known HCMV immuno-
regulatory effects. They downregulate MHC class I expres-
sion (5–10), inhibit the transporter associated with antigen
Figure 6. Jak1 protein is de-
creased by a posttranscriptional
mechanism. mRNA was isolated
from equal numbers of nonin-
fected and HCMV-infected fi-
broblasts at 72 h after infection, a
time when there is no detectable
Jak1 protein. Jak1 mRNA is not
decreased in HCMV-infected
cells despite the decrease of Jak1
protein at this time point.
Figure 7. Jak1 is degraded in infected cells. Noninfected and HCMV-
infected fibroblasts at 48 h after infection were treated with solvent
(DMSO) or Z-L3VS for 12 h. After Z-L3VS treatment, equal numbers of
cells were lysed and Jak1 was immunoprecipitated. There is an increase in
steady state levels of Jak1 protein in HCMV-infected cells treated with
Z-L3VS (lane 4). 
Figure 9. Model for HCMV inhibition of IFN-g–stimulated MHC
class II expression. HCMV IE and/or E genes disable Jak/Stat signal
transduction by decreasing Jak1 expression, which inhibits IFN-g–stimu-
lated signal transduction. Inhibiting IFN-g signaling prevents the upregu-
lation of CIITA and protein–protein interactions between CIITA and
class II promoter binding proteins that are believed to be required for
MHC class II transcription. 
Figure 8. HCMV IE and/or E genes, but not L genes, inhibit IFN-g
signaling. (A) Northern analysis shows that PFA and GCV treatment in-
hibits the expression of an L gene, gB, but not IE gene expression in HCMV-
infected fibroblasts. (B) At 72 h after infection, HCMV-infected fibroblasts,
and HCMV-infected fibroblasts treated with PFA/GCV were stimulated
with 200 U/ml IFN-g for 30 min, nuclear extracts were recovered, and
EMSA was performed. HCMV infection inhibits IFN-g–stimulated GAF
formation under conditions where only IE and E genes are expressed
(lane 6).681 Miller et al.
processing (54), and encode an MHC class I homologue
(3, 4).
In conclusion, we have demonstrated that HCMV in-
hibits inducible MHC class II expression in ECs and fibro-
blasts by disabling IFN-g stimulated signal transduction. To
our knowledge, this is the first report of a mechanism for
the HCMV-mediated disruption of inducible MHC class II
expression and the first report of a direct virus-associated
alteration in Janus kinase levels. These findings are yet an-
other example of the diverse mechanisms by which HCMV,
and thus viruses in general, are capable of avoiding immu-
nosurveillance and establishing persistence.
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